The real-world observational prospective study of health outcomes with dulaglutide and liraglutide in patients with type 2 diabetes (TROPHIES): Final, 24-month analysis of time to first significant treatment change, treatment persistence and clinical outcomes.
Humans
Diabetes Mellitus, Type 2
/ drug therapy
Glucagon-Like Peptides
/ therapeutic use
Glycated Hemoglobin
Hypoglycemic Agents
/ therapeutic use
Immunoglobulin Fc Fragments
/ therapeutic use
Liraglutide
/ therapeutic use
Outcome Assessment, Health Care
Prospective Studies
Recombinant Fusion Proteins
/ therapeutic use
TROPHIES
discontinuation
dulaglutide
glucagon-like peptide-1 receptor agonist
liraglutide
persistence
treatment change
treatment patterns
type 2 diabetes
Journal
Diabetes, obesity & metabolism
ISSN: 1463-1326
Titre abrégé: Diabetes Obes Metab
Pays: England
ID NLM: 100883645
Informations de publication
Date de publication:
12 2023
12 2023
Historique:
revised:
24
07
2023
received:
17
03
2023
accepted:
25
07
2023
medline:
13
11
2023
pubmed:
13
9
2023
entrez:
13
9
2023
Statut:
ppublish
Résumé
To present the final results of the TROPHIES study (The real-world observational prospective study of health outcomes with dulaglutide and liraglutide in patients with type 2 diabetes). The prospective, real-world TROPHIES study included patients with type 2 diabetes initiating their first injectable glucose-lowering medication (GLM), dulaglutide or liraglutide, in France, Germany and Italy. The primary endpoint was the time spent on dulaglutide or liraglutide until a significant treatment change over 24 months. Other endpoints measured persistence with treatment, clinical outcomes (glycated haemoglobin [HbA1c] and weight) and treatment patterns. Kaplan-Meier estimates of time to first significant treatment change and persistence with treatment were generated. Propensity-score-based inverse probability of treatment weighting (IPTW) was used to adjust for baseline imbalances in the comparison between cohorts. The 286 of 1014 patients (28.2%) in the dulaglutide cohort and 448 of 991 patients (45.2%) in the liraglutide cohort had a significant treatment change over 24 months. By IPTW analysis, dulaglutide-initiating patients were less likely to have a significant treatment change (hazard ratio [HR] 0.54, 95% confidence interval [CI] 0.46-0.63) and more likely to be persistent with treatment (HR 0.69, 95% CI 0.56-0.86) over 24 months than liraglutide-initiating patients. Dulaglutide and liraglutide yielded similar HbA1c (-11.80 mmol/mol [1.08%] and -11.91 mmol/mol [1.09%]) and weight (-3.5 kg and -3.3 kg) reductions from baseline to 24 months. Few changes in patterns of treatment with other GLMs were observed in the two cohorts. Dulaglutide-initiating patients had a longer time spent without any significant treatment change and higher persistence than those initiating liraglutide. Treatment with either glucagon-like peptide-1 receptor agonist yielded similar and clinically meaningful reductions in HbA1c and body weight.
Substances chimiques
dulaglutide
WTT295HSY5
Glucagon-Like Peptides
62340-29-8
Glycated Hemoglobin
0
Hypoglycemic Agents
0
Immunoglobulin Fc Fragments
0
Liraglutide
839I73S42A
Recombinant Fusion Proteins
0
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3465-3477Informations de copyright
© 2023 Eli Lilly and Company and The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.
Références
Davies MJ, D'Alessio DA, Fradkin J, et al. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of diabetes (EASD). Diabetes Care. 2018;2018(41):2669-2701.
Buse JB, Wexler DJ, Tsapas A, et al. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of diabetes (EASD). Diabetes Care. 2018;2020(43):487-493.
Davies MJ, Aroda VR, Collins BS, et al. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of diabetes (EASD). Diabetes Care. 2022;2022(45):2753-2786.
American Diabetes Association. Standards of medical care in diabetes-2022 abridged for primary care providers. Clin Diabetes. 2022;40:10-38.
Divino V, DeKoven M, Khan FA, Boye KS, Sapin H. Norrbacka K.GLP-1 RA treatment patterns among type 2 diabetes patients in five European countries. Diabetes Ther. 2017;8:115-128.
Divino V, Boye KS, Lebrec J, DeKoven M. Norrbacka K.GLP-1 RA treatment and dosing patterns among type 2 diabetes patients in six countries: a retrospective analysis of pharmacy claims data. Diabetes Ther. 2019;10:1067-1088.
Anderson JE, Thieu VT, Boye KS, Hietpas RT, Garcia-Perez LE. Dulaglutide in the treatment of adult type 2 diabetes: a perspective for primary care providers. Postgrad Med. 2016;128:810-821.
Alatorre C, Fernández Landó L, Yu M, et al. Treatment patterns in patients with type 2 diabetes mellitus treated with glucagon-like peptide-1 receptor agonists: higher adherence and persistence with dulaglutide compared with once-weekly exenatide and liraglutide. Diabetes Obes Metab. 2017;19:953-961.
Federici MO, McQuillan J, Biricolti G, et al. Utilization patterns of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus in Italy: a retrospective cohort study. Diabetes Ther. 2018;9:789-801.
Mody R, Huang Q, Yu M, et al. Adherence, persistence, glycaemic control and costs among patients with type 2 diabetes initiating dulaglutide compared with liraglutide or exenatide once weekly at 12-month follow-up in a real-world setting in the United States. Diabetes Obes Metab. 2019;21:920-929.
Norrbacka K, Sicras-Mainar A, Lebrec J, et al. Glucagon-like peptide 1 receptor agonists in type 2 diabetes mellitus: data from a real-world study in Spain. Diabetes Ther. 2021;12:1535-1551.
Brown RE, Abitbol A, Bajaj HS, et al. Patient reported outcomes following initiation of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes in a specialist endocrinology practice of the LMC diabetes registry: the PROGRESS-diabetes study. Diabetes Res Clin Pract. 2019;156:107820.
Bossi AC, De Mori V, Scaranna C, et al. ANDREW: a multicenter, prospective, observational study in patients with type 2 diabetes on persistent treatment with dulaglutide. Diabetes Ther. 2020;11:2677-2690.
Gautier JF, Martinez L, Penfornis A, et al. Effectiveness and persistence with liraglutide among patients with type 2 diabetes in routine clinical practice-EVIDENCE: a prospective, 2-year follow-up, observational, post-marketing study. Adv Ther. 2015;32:838-853.
Buysschaert M, D'Hooge D, Preumont V, Roots Study Group. ROOTS: a multicenter study in Belgium to evaluate the effectiveness and safety of liraglutide (Victoza®) in type 2 diabetic patients. Diabetes Metab Syndr. 2015;9:139-142.
García-Pérez LE, Boye KS, Rosilio M, et al. The real-world observational prospective study of health outcomes with dulaglutide and liraglutide in type 2 diabetes patients (TROPHIES): design and baseline characteristics. Diabetes Ther. 2021;12:1929-1946.
Guerci B, Giorgino F, Sapin H, et al. The real-world observational prospective study of health outcomes with dulaglutide and liraglutide in type 2 diabetes patients (TROPHIES): patient disposition, clinical characteristics, and treatment persistence at 12 months. Diabetes Obes Metab. 2022;24:2372-2382.
European Medicines Agency, Trulicity. Product information. https://www.ema.europa.eu/en/documents/product-information/trulicity-epar-product-information_en.pdf. Accessed 08 September 2022
European Medicines Agency, Victoza. Product information. https://www.ema.europa.eu/en/documents/product-information/victoza-epar-product-information_en.pdf. Accessed 08 March 2022
World Medical Association. Declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. JAMA. 1997;277:925-926.
Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70:41-55.
Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med. 2015;34:3661-3679.
Darmon P, Bauduceau B, Bordier L, et al. Prise de position de la Société Francophone du Diabéte (SFD) sur la prise en charge médicamenteuse de l'hyperglycémie du patient diabétique de type 2. Méd mal Métabol. 2017;11:577-593.
Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311-322.
Base De Données Publique Des Médicaments. Forxiga. https://base-donnees-publique.medicaments.gouv.fr/extrait.php?specid=67456363
Polonsky WH, Arora R, Faurby M, Fernandes J, Liebl A. Higher rates of persistence and adherence in patients with type 2 diabetes initiating once-weekly vs daily injectable glucagon-like peptide-1 receptor agonists in US clinical practice (STAY study). Diabetes Ther. 2022;13:175-187.
Zimner Rapuch S, Divino V, Norrbacka K, et al. Treatment patterns and persistence with GLP-1 RA treatments among patients with type 2 diabetes in France: a retrospective cohort analysis. Diabetes Ther. 2021;12:1553-1567.
Buysman EK, Liu F, Hammer M, Langer J. Impact of medication adherence and persistence on clinical and economic outcomes in patients with type 2 diabetes treated with liraglutide: a retrospective cohort study. Adv Ther. 2015;32:341-355.
Lin J, Lingohr-Smith M, Fan T. Real-world medication persistence and outcomes associated with basal insulin and glucagon-like peptide 1 receptor agonist free-dose combination therapy in patients with type 2 diabetes in the US. Clinicoecon Outcomes Res. 2016;9:19-29.
Tanaka K, Okada Y, Tokutsu A, Tanaka Y. Real-world effectiveness of liraglutide versus dulaglutide in Japanese patients with type 2 diabetes: a retrospective study. Sci Rep. 2022;12:154.
Dungan KM, Povedano ST, Forst T, et al. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. Lancet. 2014;384:1349-1357.
Robinson S, Boye KS, Mody R, et al. Real-world effectiveness of dulaglutide in patients with type 2 diabetes mellitus: a literature review. Diabetes Ther. 2020;11:1437-1466.